A pivotal study for Voclosporin, known as the AURORA trial, which investigated renal response in active lupus, was published on 2011-01-01. This publication marks a significant update for the drug in the context of lupus nephritis, highlighting its development pathway.
Background
Voclosporin is a drug that has been investigated for its potential role in treating lupus nephritis. The AURORA study specifically focused on assessing its efficacy in achieving renal response in patients diagnosed with active lupus.
What this means
The publication of the AURORA trial represents a key milestone in the development of Voclosporin for lupus nephritis. While specific trial outcomes are not detailed in this update, its designation as a 'pivotal' study indicates its importance in the drug's development pathway. Clinicians and researchers will refer to the full publication for detailed efficacy and safety data.
Source
The information regarding this pivotal publication was sourced from PubMed, referencing a document titled 'Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.' The publication date was 2011-01-01, and it is available on pubmed.ncbi.nlm.nih.gov.